VivoSeq
Oncology

Follicular Lymphoma

165

Pipeline Programs↗

68

Active Trials↗

65

Companies Involved↗

Follicular Lymphoma is a highly competitive landscape with 165 programs across 65 companies. The most active players are ADC Therapeutics S.A., Boehringer Ingelheim, Allogene Therapeutics. 8 therapies are approved with 40 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

79/100

Pipeline Velocity

39/100

Mech. Concentration

7/100

Completion Rate

66/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

ADC Therapeutics S.A.

1 program

Phase 1Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 1A

Allogene Therapeutics

1 program

Phase 1C

Cho Pharma Inc.

1 program

Phase 1S

Sebela Pharmaceuticals Development LLC

1 program

Phase 1I

Iovance Biotherapeutics, Inc.

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

75%

Small molecule

129 of 171 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody2313%Vaccine64%Antibody–drug conjugate42%Protein / enzyme42%Cell therapy42%Peptide1<1%

Small molecule leads; the ring shows all 171 classified programs, each share of the total. Modality classified for 95% of 202 pipeline programs.

Analysis

Trial Status

219

clinical trials

Completed85 · 39%
Terminated32 · 15%
Recruiting30 · 14%
Active, not recruiting25 · 11%
Unknown status22 · 10%
Not yet recruiting13 · 6%
Other12 · 5%

Clinical Trials

Trial Activity

219 trials

Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
Recruiting·—·Phase 2·NCT06471738·30 enrolled
Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients
Recruiting·FFondazione Italiana Linfomi - ETS·Phase 2·NCT06492837·56 enrolled
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06043323·20 enrolled
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06108232·36 enrolled
Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma
Recruiting·WWeill Medical College of Cornell University·Phase 2·NCT05994235·50 enrolled
MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma
Recruiting·BBeijing Mabworks Biotech Co., Ltd.·Phase 3·NCT04834024·168 enrolled
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
Recruiting·Regeneron logoRegeneron·Phase 3·NCT06149286·470 enrolled
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
Recruiting·UUniversity of Birmingham·Phase 2·NCT05848765·284 enrolled
Epcoritamab and Rituximab for First-line Follicular Lymphoma
Recruiting·—·Phase 2·NCT05783609·100 enrolled
Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07418190·33 enrolled
Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma
Recruiting·—·Phase 2·NCT06453044·41 enrolled
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
Recruiting·UUniversity of Washington·Phase 2·NCT06948786·22 enrolled
Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma
Recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 2·NCT06826118·30 enrolled
Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries
Recruiting·OOslo University Hospital·Phase 2·NCT05849857·80 enrolled
Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).
Recruiting·AAndrés José Maria Ferreri·N/A·NCT07278921·25 enrolled
Page 1 of 15

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)